Equities research analysts at HC Wainwright initiated coverage on shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) in a report released on Tuesday. The firm set a “buy” rating and a $5.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 52.44% from the company’s previous close.

Several other research firms also recently weighed in on DRNA. Zacks Investment Research raised Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. Leerink Swann initiated coverage on Dicerna Pharmaceuticals in a report on Tuesday, January 31st. They issued a “market perform” rating and a $4.00 target price for the company. Jefferies Group LLC reissued a “buy” rating and issued a $7.00 target price (down from $8.00) on shares of Dicerna Pharmaceuticals in a report on Sunday, April 2nd. Finally, Cowen and Company reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 9th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $5.88.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at 3.28 on Tuesday. The firm’s market capitalization is $68.20 million. The stock has a 50 day moving average price of $3.20 and a 200-day moving average price of $3.02. Dicerna Pharmaceuticals has a one year low of $2.42 and a one year high of $6.10.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by $0.03. The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.08 million. On average, analysts predict that Dicerna Pharmaceuticals will post ($2.31) earnings per share for the current fiscal year.

WARNING: “Dicerna Pharmaceuticals Inc (DRNA) Earns Buy Rating from Analysts at HC Wainwright” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/05/23/dicerna-pharmaceuticals-inc-drna-earns-buy-rating-from-analysts-at-hc-wainwright.html.

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Dicerna Pharmaceuticals by 0.3% in the first quarter. Vanguard Group Inc. now owns 325,810 shares of the biopharmaceutical company’s stock valued at $1,108,000 after buying an additional 1,086 shares during the last quarter. RTW Investments LP boosted its position in Dicerna Pharmaceuticals by 0.8% in the fourth quarter. RTW Investments LP now owns 2,043,216 shares of the biopharmaceutical company’s stock valued at $5,884,000 after buying an additional 16,322 shares during the last quarter. Renaissance Technologies LLC boosted its position in Dicerna Pharmaceuticals by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 408,682 shares of the biopharmaceutical company’s stock valued at $1,177,000 after buying an additional 84,682 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Dicerna Pharmaceuticals by 7.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,978 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 2,705 shares during the last quarter. Finally, Oxford Asset Management boosted its position in Dicerna Pharmaceuticals by 109.3% in the second quarter. Oxford Asset Management now owns 286,413 shares of the biopharmaceutical company’s stock valued at $859,000 after buying an additional 149,560 shares during the last quarter. 58.56% of the stock is owned by hedge funds and other institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

12 Month Chart for NASDAQ:DRNA

Receive News & Ratings for Dicerna Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.